<DOC>
	<DOC>NCT00195000</DOC>
	<brief_summary>The purpose of this study is to find out how safe and effective the combination of Mylotarg in combination with cytarabine is in treating patients with Acute Myeloid Leukemia and advanced Myelodysplastic Syndrome over the age of 60 years.</brief_summary>
	<brief_title>Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS</brief_title>
	<detailed_description>To evaluate the safety and efficacy of gemtuzumab ozogamicin in combination with cytarabine in inducing complete remission in patients with AML and advanced MDS over the age of 60 years. Patients eligible for treatment will receive the following: Mylotarg at 6 mg/m2 on day 1 as a 2 hour intravenous infusion Cytarabine at 100 mg/m2/day as a continuous intravenous infusion daily for 7 days</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Histologic diagnosis of AML or advanced MDS No prior cytotoxic treatment for AML. (patients may have been treated with prior biologic therapy) Patients with MDS or AML that has evolved from MDS, could have received prior lowdose cytotoxic therapy (i.e. azacytidine or lowdose araC). Uncontrolled or severe cardiovascular disease or pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>